# CAST-AI (NCT06764095)

> Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

No report yet. It can be ordered.

- Drugs tested: enfortumab vedotin plus pembrolizumab
- Indication: locally advanced or metastatic urothelial carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06764095
- Phase: PHASE4
- Status: RECRUITING
- Sponsor: Mayo Clinic
- Conditions: Locally Advanced Bladder Urothelial Carcinoma; Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma; Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma; Stage III Bladder Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Stage IV Renal Pelvis and Ureter Cancer AJCC v8
- Interventions: Biospecimen Collection; Computed Tomography; Cystectomy; Enfortumab Vedotin; Local Therapy; Magnetic Resonance Imaging; Pembrolizumab; Positron Emission Tomography; Questionnaire Administration; Ureterectomy
- Enrollment: 75
- Primary outcome: Progression-free survival (PFS) at 12 months

## Indexed commentary on CAST-AI so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=cast-ai-nct06764095